DGIdb - NIVOLUMAB Drug Record

NIVOLUMAB chembl:CHEMBL2108738 ApprovedAntineoplastic

Alternate Names:

ONO-4538
OPDIVO
MDX-1106
NIVOLUMAB
BMS-936558
drugbank:09035
rxcui:1597876
chembl:CHEMBL2108738
chemidplus:946414-94-4

Drug Info:

FDA Approval	not approved
Drug Class	monoclonal antibody
Drug Indications	antineoplastic agent
FDA Approval	Head and neck squamous cell carcinoma, Hodgkin lymphoma, Melanoma, Non-small cell lung cancer, Renal cell carcinoma, Urothelial carcinoma
Drug Class	Therapeutic Antibodies

(8 More Sources)

Publications:

Carbognin et al., 2015, Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers., PLoS ONE
Aguiar et al., 2017, PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data., Immunotherapy
Passiglia et al., 2016, PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis., Oncotarget
Kim et al., 2017, Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review., Oncotarget
Gainor et al., 2016, EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis., Clin. Cancer Res.
Haratani et al., 2017, Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment., Ann. Oncol.
Hastings K et al., 2019, EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer., Ann Oncol
Bouffet et al., 2016, Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency., J. Clin. Oncol.
Taneja, 2012, Re: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer., J. Urol.
Peng et al., 2016, Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy., Cancer Discov
Zhao J et al., 2019, Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma., Nat Med
Skoulidis F et al., 2018, <i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma., Cancer Discov
Johnson et al., 2016, Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy., Nat Commun
Braun DA et al., 2019, Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma., JAMA Oncol
Miao D et al., 2018, Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma., Science
Kato et al., 2017, Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate., Clin. Cancer Res.
Shen J et al., 2018, ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade., Nat Med

NIVOLUMAB PMS2

Interaction Score: 8.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27001570

Sources:
CIViC
NIVOLUMAB CD274

Interaction Score: 2.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26086854 28472902 26918451

Sources:
CIViC PharmGKB FDA
NIVOLUMAB PDCD1

Interaction Score: 1.77

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Novel drug target Novel Target

Trial Name BMS-936558, ONO-4538, MDX-1106

Direct Interaction yes

PMIDs:
23289116

Sources:
MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TTD
NIVOLUMAB ARID1A

Interaction Score: 1.65

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29736026

Sources:
CIViC
NIVOLUMAB MDM4

Interaction Score: 1.65

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28351930

Sources:
CIViC
NIVOLUMAB PBRM1

Interaction Score: 1.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31486842 29301960

Sources:
CIViC
NIVOLUMAB HLA-DRA

Interaction Score: 1.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26822383

Sources:
CIViC
NIVOLUMAB MDM2

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28351930

Sources:
CIViC
NIVOLUMAB CDK12

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
OncoKB
NIVOLUMAB STK11

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29773717

Sources:
CIViC
NIVOLUMAB ALK

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Clinical Study

Response Type decreased response

PMIDs:
27225694

Sources:
JAX-CKB PharmGKB FDA
NIVOLUMAB EGFR

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type non-small cell lung carcinoma

Response Type decreased response

Approval Status Clinical Study

PMIDs:
27225694 28407039 31086949

Sources:
JAX-CKB CIViC PharmGKB FDA
NIVOLUMAB PTEN

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Clinical Study

PMIDs:
26645196 30742119

Sources:
JAX-CKB CIViC
NIVOLUMAB BRAF

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
NIVOLUMAB KRAS

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28525386

Sources:
CIViC

MyCancerGenome: NIVOLUMAB
- Version: 20-Jun-2017
Alternate Names:

BMS-936558 Development Name

MDX-1106 Development Name

ONO-4538 Development Name

Drug Info:

Drug Class Therapeutic Antibodies

FDA Approval Head and neck squamous cell carcinoma, Hodgkin lymphoma, Melanoma, Non-small cell lung cancer, Renal cell carcinoma, Urothelial carcinoma

Publications:
TdgClinicalTrial: MDX-1106
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class monoclonal antibody

FDA Approval not approved

Publications:

JAX-CKB: Nivolumab

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Peng et al., 2016, Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy., Cancer Discov

Gainor et al., 2016, EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis., Clin. Cancer Res.

Haratani et al., 2017, Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment., Ann. Oncol.

PharmGKB: nivolumab

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Carbognin et al., 2015, Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers., PLoS ONE

CIViC: NIVOLUMAB

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Hastings K et al., 2019, EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer., Ann Oncol

Passiglia et al., 2016, PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis., Oncotarget

Carbognin et al., 2015, Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers., PLoS ONE

TALC: NIVOLUMAB
- Version: 12-May-2016
Alternate Names:

NIVOLUMAB Primary Drug Name

NIVOLUMAB Drug Generic Name

MDX-1106 Drug Synonym

Drug Info:

Publications:
TTD: Nivolumab
- Version: 2020.06.01
Alternate Names:

D00GOV TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL2108738
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
OncoKB: Nivolumab
- Version: 23-July-2020
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL2108738
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
FDA: Nivolumab
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: NIVOLUMAB
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:

Novel drug target	Novel Target
Trial Name	BMS-936558, ONO-4538, MDX-1106
Direct Interaction	yes

Evidence Type	Actionable
Approval Status	Clinical Study
Response Type	decreased response

Indication/Tumor Type	non-small cell lung carcinoma
Response Type	decreased response
Approval Status	Clinical Study

Indication/Tumor Type	melanoma
Response Type	sensitive
Approval Status	Clinical Study

BMS-936558	Development Name
MDX-1106	Development Name
ONO-4538	Development Name

NIVOLUMAB	Primary Drug Name
NIVOLUMAB	Drug Generic Name
MDX-1106	Drug Synonym

antibody (inhibitory)
inhibitor (inhibitory)

NIVOLUMAB Drug Record

NIVOLUMAB chembl:CHEMBL2108738 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27001570

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26086854 28472902 26918451

Sources: CIViC PharmGKB FDA

Interaction Types & Directionality: antibody (inhibitory) inhibitor (inhibitory)

Interaction Info: Novel drug target Novel Target Trial Name BMS-936558, ONO-4538, MDX-1106 Direct Interaction yes

PMIDs: 23289116

Sources: MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29736026

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28351930

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31486842 29301960

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26822383

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28351930

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: OncoKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29773717

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Clinical Study Response Type decreased response

PMIDs: 27225694

Sources: JAX-CKB PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type non-small cell lung carcinoma Response Type decreased response Approval Status Clinical Study

PMIDs: 27225694 28407039 31086949

Sources: JAX-CKB CIViC PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type melanoma Response Type sensitive Approval Status Clinical Study

PMIDs: 26645196 30742119

Sources: JAX-CKB CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28525386

Sources: CIViC

MyCancerGenome: NIVOLUMAB

Alternate Names: BMS-936558 Development Name MDX-1106 Development Name ONO-4538 Development Name

Drug Info: Drug Class Therapeutic Antibodies FDA Approval Head and neck squamous cell carcinoma, Hodgkin lymphoma, Melanoma, Non-small cell lung cancer, Renal cell carcinoma, Urothelial carcinoma

Publications:

TdgClinicalTrial: MDX-1106

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class monoclonal antibody FDA Approval not approved

Publications:

JAX-CKB: Nivolumab

Alternate Names:

Drug Info:

PharmGKB: nivolumab

Alternate Names:

Drug Info:

Publications: Carbognin et al., 2015, Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers., PLoS ONE

Interaction Types & Directionality:

n/a

PMIDs:
27001570

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
26086854 28472902 26918451

Sources:
CIViC PharmGKB FDA

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Novel drug target Novel Target

Trial Name BMS-936558, ONO-4538, MDX-1106

Direct Interaction yes

PMIDs:
23289116

Sources:
MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality:

n/a

PMIDs:
29736026

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
28351930

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
31486842 29301960

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
26822383

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
28351930

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
OncoKB

Interaction Types & Directionality:

n/a

PMIDs:
29773717

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Clinical Study

Response Type decreased response

PMIDs:
27225694

Sources:
JAX-CKB PharmGKB FDA

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type non-small cell lung carcinoma

Response Type decreased response

Approval Status Clinical Study

PMIDs:
27225694 28407039 31086949

Sources:
JAX-CKB CIViC PharmGKB FDA

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type sensitive

Approval Status Clinical Study

PMIDs:
26645196 30742119

Sources:
JAX-CKB CIViC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
28525386

Sources:
CIViC

Alternate Names:

BMS-936558 Development Name

MDX-1106 Development Name

ONO-4538 Development Name

Drug Info:

Drug Class Therapeutic Antibodies

FDA Approval Head and neck squamous cell carcinoma, Hodgkin lymphoma, Melanoma, Non-small cell lung cancer, Renal cell carcinoma, Urothelial carcinoma

Drug Info:

Drug Indications antineoplastic agent

Drug Class monoclonal antibody

FDA Approval not approved

Publications:

Carbognin et al., 2015, Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers., PLoS ONE

Alternate Names:

NIVOLUMAB Primary Drug Name

NIVOLUMAB Drug Generic Name

MDX-1106 Drug Synonym

Alternate Names:

D00GOV TTD Drug ID